Congenital hyperinsulinism due to mutations in HNF1A.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 25 07 2019
revised: 04 03 2020
accepted: 11 04 2020
pubmed: 24 4 2020
medline: 30 12 2020
entrez: 24 4 2020
Statut: ppublish

Résumé

Congenital hyperinsulinism is a rare but significant cause of severe and persistent hypoglycaemia in infancy. Although a biphasic phenotype of congenital hyperinsulinism in infancy followed by Maturity-Onset Diabetes of the Young (MODY) in later life has been established for HNF4A, the existence of a similar phenotype for a related MODY gene, HNF1A, is less clear. We describe two cases of congenital hyperinsulinism in association with dominantly inherited variants in HNF1A. They presented in the early neonatal period with unequivocal biochemical evidence of congenital hyperinsulinism and persistence into childhood with ongoing need for medical therapy. Both cases inherited HNF1A variants from a parent with a diabetes phenotype consistent with MODY, without obesity, insulin resistance or other metabolic syndrome features. In the first case, a paternally inherited novel c.-230_-101del variant was found that deletes the minimal promoter region presumably required for HNF1A expression. In the second case, a maternally inherited missense variant (c.713G>T, p.(Arg238Met)) was identified. This variant is predicted to cause haploinsufficiency via aberrant splicing and has previously been associated with MODY but not congenital hyperinsulinism. Our cases further strengthen the evidence for HNF1A as a CHI-causing gene requiring long-term follow-up.

Identifiants

pubmed: 32325224
pii: S1769-7212(19)30503-8
doi: 10.1016/j.ejmg.2020.103928
pii:
doi:

Substances chimiques

HNF1A protein, human 0
Hepatocyte Nuclear Factor 1-alpha 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103928

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Daphne Yau (D)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK. Electronic address: daphne.yau@mail.mcgill.ca.

Kevin Colclough (K)

Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.

Anuja Natarajan (A)

Doncaster Royal Infirmary, Doncaster, UK.

Ruchi Parikh (R)

Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK.

Natalie Canham (N)

Liverpool Women's Hospital, Liverpool, UK.

Mohammed Didi (M)

Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK.

Senthil Senniappan (S)

Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK.

Indraneel Banerjee (I)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH